CompletedPhase 3NCT05795699

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Studying Corneal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kowa Research Institute, Inc.
Principal Investigator
Shona Pendse, MD, MMSc
Kowa Pharma Development Co.
Intervention
Ripasudil(drug)
Enrollment
107 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05795699 on ClinicalTrials.gov

Other trials for Corneal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Corneal dystrophy

← Back to all trials